We would like to announce that the Center for Disease Control (CDC) has a call for a proposal entitled “Reducing the Tuberculosis Burden in U.S. Bound Populations from the Philippines”
Call Description: Immigrant and refugee applicants for US immigration are required to undergo a medical examination pursuant to section 232 of the Immigration and Nationality Act (INA) (8 U.S.C. 1222). Sections 212(a)(1) and 232 of the INA, and section 325 of the Public Health Service (PHS) Act (42 U.S.C. 252) grant the Secretary of Health and Human Services (HHS) authority to publish regulations that establish the requirements for, and components of, the medical examination of aliens. HHS/CDC Part 34 regulations entitled Medical Examination of Aliens regulations also define the communicable diseases of public health significance that make aliens inadmissible to the United States and provide that all medical examinations shall be carried out in accordance with the Technical Instructions for physicians conducting the medical examination of aliens as may be issued by the Director of Quarantine.
This NOFO is intended to implement strategies to reduce the incidence of TB in the Philippines and to reduce the tuberculosis burden in US bound populations from the Philippines in order to reduce the burden needed to be detected by US panel physicians. The aim is to engage public health officials to develop and implement a system to identify persons at risk of TB infection; provide training support to regions with elevated rates of TB and drug-resistant TB; build the capacity of local jurisdictions to treat and care for individuals with TB; and develop and implement trainings for public health partners to increase knowledge and promote TB identification, diagnosis, and treatment best practices.
The due date for the submission of the application is on May 1, 2022.
For further details you may visit this link: https://www.grants.gov/web/grants/search-grants.html?keywords=TB%20Philippines
We are pleased to announce that the Office of the Executive Director, National Institutes of Health is now accepting the applications for the UPM Student Researcher Grant for CY2022. The grants provides funding support for thesis/research of UP Manila undergraduate students, medical students, and masteral students without any scholarship.
The deadline for submission is on 28 February 2022.
For more details please download this file: UPM Student Research Grant 2022
We are pleased to announce that the Philippine Council for Health Research and Development (PCHRD) has a new call for proposals that are focused on OMIC Technologies for Health Program.
The OMIC Technologies for Health Program utilizes information from different ‘OMIC’ technologies, such as genomics, transcriptomics, proteomics, metabolomics and bioinformatics, as input to the development of precision medicine, diagnostics, therapeutics, and as a support to health & clinical practice guidelines and policies of the Philippines.
The continuity of the country’s long-term investments in OMICS research is ensured in this current Call for Proposals, which will focus on building on the collective success of the previous projects and programs while encouraging the submission of proposals on other important but often overlooked health research and policy issues. Neuroscience OMICS, cancer research, researches on rare diseases, translational studies on CDs, and population and forensic studies will be at the forefront, along with the possible adaptation of the genomic biosurveillance model developed for SARS-CoV-2 strains to other emerging and re-emerging disease.
Submission period: 01 March 2022 – 31 March 2022 (5PM) via the DOST DPMIS (https://dpmis.dost.gov.ph/)
For more information you may download this file: Call for Proposal OMIC Technologies for Health Program
We are pleased to announce that the Orphan Disease Center and Loulou Foundation has released a call for grant that will support research related to CDKL5 Deficiency Disorder (CDD). CDKL5 Deficiency Disorder (CDD) is a monogenic, neurodevelopmental disorder characterized by treatment-resistant epilepsy and severe neurodevelopmental delay. The disease is driven by the loss of a kinase called CDKL5 which is responsible for normal neuronal development, synapse formation, and signal transmission. The mechanisms by which loss of CDKL5 expression leads to this CNS disorder remain unclear. The gene encoding this protein is located on the X chromosome, with heterozygous females primarily affected. The disease does not exhibit neurodegeneration, and animal models strongly suggest the potential for reversibility. There are no approved therapies and the current standard of care is not effective at managing seizures or improving neurodevelopmental or motor deficits.
Letters of Interest (LOIs) are due no later than FRIDAY, FEBRUARY 25, 2022, by 5pm EST. Grant criteria, the entire RFA, and additional program details can be found here.
For more details you may download the attached file: